Laden…
3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
Risperidone is an atypical antipsychotic that primarily acts by blocking dopamine D2 and serotonin 5-HT2A receptors. It is used for the treatment of schizophrenia and bipolar disorders. The substance can cause side effects such as extrapyramidal symptoms and metabolic changes. Due to its pharmacological profile, it is often used as an alternative to classical neuroleptics.
Receptor Targets
Mechanism of Action
Designations
IUPAC: 3-[2-[4-(6-fluoroindoxazen-3-yl)piperidino]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
Legal Status
Legal status not verified by official sources. Please check current legislation independently.
Information without guarantee. Not legal advice.
Receptor Profile
Der 5-HT2A-Rezeptor ist ein Serotonin-Rezeptor der Klasse Gq-gekoppelter GPCRs. Er ist der primäre molekulare Angriffspunkt klassischer Psychedelika und spielt eine Rolle bei Kognition und Wahrnehmung.
Der D2-Rezeptor ist ein Gi-gekoppelter Dopaminrezeptor mit hoher Dichte im Striatum. Er ist ein wichtiges Ziel für Antipsychotika und moduliert motorische Funktionen sowie Belohnungsverarbeitung.
Der Serotonintransporter (SERT/5-HTT) ist ein Natrium-abhängiger Monoamintransporter, der Serotonin aus dem synaptischen Spalt zurück in die präsynaptische Zelle transportiert. Er ist das primäre Ziel von SSRI und MDMA.
Der H1-Rezeptor ist ein Gq/11-gekoppelter Histaminrezeptor, der an allergischen Reaktionen, Wachheit und Thermoregulation beteiligt ist. Antagonismus verursacht Sedierung und wird therapeutisch als Schlafhilfe und Antiallergikum genutzt.
Substance Fingerprint
Pharmacological profile based on receptor binding, mechanism of action, and substance class. Limited data — interpret profile with caution.
Synapedia Evidence
Effects & Pharmacology is partially translated. Some content may appear in German.
Risperidon wirkt als Antagonist an Dopamin-D2- und Serotonin-5-HT2A-Rezeptoren, was zur Reduktion von psychotischen Symptomen führt.
Known Effects
Individual effects may vary significantly. These are pharmacologically documented effects.
Total duration 24 hours
Peak
4-6 hours
Onset
1-2 hours
Total duration
24 hours
Start low. Individual sensitivity varies.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, combinations, and pre-existing conditions significantly affect outcomes. These figures are not dosing recommendations — they describe reported ranges, not safe amounts.
Risks
Summary
Mögliche Nebenwirkungen umfassen Gewichtszunahme, Sedierung und extrapyramidale Symptome.
Safer Use
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Interaction details from the knowledge layer are still being translated.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
The signal hub collects approved risk signals, experience reports and source leads by relevance.